

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT												
NATURE OF CONVEYANCE:	ASSIGNMENT												
CONVEYING PARTY DATA													
<table border="1"><thead><tr><th>Name</th><th>Execution Date</th></tr></thead><tbody><tr><td>Mike Rothe</td><td>10/10/2010</td></tr><tr><td>Norbert Prenzel</td><td>10/20/2010</td></tr><tr><td>Eric Borges</td><td>10/12/2010</td></tr><tr><td>Thore Hettmann</td><td>10/13/2010</td></tr><tr><td>Esther Zwick-Wallasch</td><td>10/13/2010</td></tr></tbody></table>		Name	Execution Date	Mike Rothe	10/10/2010	Norbert Prenzel	10/20/2010	Eric Borges	10/12/2010	Thore Hettmann	10/13/2010	Esther Zwick-Wallasch	10/13/2010
Name	Execution Date												
Mike Rothe	10/10/2010												
Norbert Prenzel	10/20/2010												
Eric Borges	10/12/2010												
Thore Hettmann	10/13/2010												
Esther Zwick-Wallasch	10/13/2010												
RECEIVING PARTY DATA													
<table border="1"><tr><td>Name:</td><td>U3 Pharma GmbH</td></tr><tr><td>Street Address:</td><td>Frauenhoferstr. 22</td></tr><tr><td>City:</td><td>Martinsried</td></tr><tr><td>State/Country:</td><td>GERMANY</td></tr><tr><td>Postal Code:</td><td>82152</td></tr></table>		Name:	U3 Pharma GmbH	Street Address:	Frauenhoferstr. 22	City:	Martinsried	State/Country:	GERMANY	Postal Code:	82152		
Name:	U3 Pharma GmbH												
Street Address:	Frauenhoferstr. 22												
City:	Martinsried												
State/Country:	GERMANY												
Postal Code:	82152												
PROPERTY NUMBERS Total: 1													
<table border="1"><thead><tr><th>Property Type</th><th>Number</th></tr></thead><tbody><tr><td>Application Number:</td><td>12680191</td></tr></tbody></table>		Property Type	Number	Application Number:	12680191								
Property Type	Number												
Application Number:	12680191												
CORRESPONDENCE DATA													
Fax Number: (650)332-1800 <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>													
Phone: (650) 325-0220													
Email: birgit@chsblaw.com													
Correspondent Name: Birgit Millauer													
Address Line 1: 770 Menlo Ave, Suite 205													
Address Line 4: Menlo Park, CALIFORNIA 94025													
ATTORNEY DOCKET NUMBER:	0150-003US1												
NAME OF SUBMITTER:	Birgit Millauer												

OP \$40.00 12680191

501405815

PATENT
REEL: 025637 FRAME: 0317

Total Attachments: 8

source=Recordassign_U3150_004001#page1.tif

source=Recordassign_U3150_004001#page2.tif

source=Recordassign_U3150_004001#page3.tif

source=Recordassign_U3150_004001#page4.tif

source=Recordassign_U3150_004001#page5.tif

source=Recordassign_U3150_004001#page6.tif

source=Recordassign_U3150_004001#page7.tif

source=Recordassign_U3150_004001#page8.tif

PATENT

REEL: 025637 FRAME: 0318


ASSIGNMENT

For valuable consideration, we, Mike Rothe, of Elisenstrasse 4, 82152 Krailling, Germany; Norbert Prenzel, of Pentenriederstrasse 32, 82152 Krailling, Germany; Eric Borges, of Roseggergasse 25, 2344 Maria Enzersdorf, Austria; Thore Hettmann, of Hirschgartenallee 14, 80639 Munich, Germany; Esther Zwick-Wallasch, of Fruehlingsstrasse 112, 82131 Gauting, Germany, hereby assign to U3 PHARMA GMBH, a corporation of Germany, having a place of business at:

Fraunhoferstrasse 22
82152 Martinsried
Germany; and

its successors and assigns, (collectively hereinafter called "the Assignee"), the entire right, title and interest throughout the world in the inventions and improvements which are subject of an application for United States Patent signed by us, entitled HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR BINDING PROTEINS, filed on September 26, 2008 as PCT International Application No. PCT/EP2008/08233, which was nationalized in the U.S. on March 25, 2010 and assigned U.S. Application Serial No. 12/680,191, this assignment including said application, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our name or in its own name for patents, utility models, design registrations and like rights of exclusion and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment.

DATE: Oct. 12, 2010


MIKE ROTHE

DATE: _____

NORBERT PRENZEL

DATE: _____

ERIC BORGES

DATE: _____

THORE HETTMANN

DATE: _____

ESTHER ZWICK-WALLASCH

U3 Pharma Assignment.doc

ASSIGNMENT

For valuable consideration, we, Mike Rothe, of Elisenstrasse 4, 82152 Krailling, Germany; Norbert Prenzel, of Pentenriederstrasse 32, 82152 Krailling, Germany; Eric Borges, of Roseggergasse 25, 2344 Maria Enzersdorf, Austria; Thore Hettmann, of Hirschgartenallee 14, 80639 Munich, Germany; Esther Zwick-Wallasch, of Fruehlingsstrasse 112, 82131 Gauting, Germany, hereby assign to U3 PHARMA GMBH, a corporation of Germany, having a place of business at:

Fraunhoferstrasse 22
82152 Martinsried
Germany; and

its successors and assigns, (collectively hereinafter called "the Assignee"), the entire right, title and interest throughout the world in the inventions and improvements which are subject of an application for United States Patent signed by us, entitled HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR BINDING PROTEINS, filed on September 26, 2008 as PCT International Application No. PCT/EP2008/08233, which was nationalized in the U.S. on March 25, 2010 and assigned U.S. Application Serial No. 12/680,191, this assignment including said application, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our name or in its own name for patents, utility models, design registrations and like rights of exclusion and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment.

DATE: _____

MIKE ROTHE

DATE: 20/10/2010

N. Prenzel

NORBERT PRENZEL

DATE: _____

ERIC BORGES

DATE: _____

THORE HETTMANN

DATE: _____

ESTHER ZWICK-WALLASCH

U3 Pharma Assignment.doc

ASSIGNMENT

For valuable consideration, we, Mike Rothe, of Elisenstrasse 4, 82152 Krailling, Germany; Norbert Prenzel, of Pentenriederstrasse 32, 82152 Krailling, Germany; Eric Borges, of Roseggergasse 25, 2344 Maria Enzersdorf, Austria; Thore Hettmann, of Hirschgartenallee 14, 80639 Munich, Germany; Esther Zwick-Wallasch, of Fruehlingsstrasse 112, 82131 Gauting, Germany, hereby assign to U3 PHARMA GMBH, a corporation of Germany, having a place of business at:

Fraunhoferstrasse 22
82152 Martinsried
Germany; and

its successors and assigns, (collectively hereinafter called "the Assignee"), the entire right, title and interest throughout the world in the inventions and improvements which are subject of an application for United States Patent signed by us, entitled HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR BINDING PROTEINS, filed on September 26, 2008 as PCT International Application No. PCT/EP2008/08233, which was nationalized in the U.S. on March 25, 2010 and assigned U.S. Application Serial No. 12/680,191, this assignment including said application, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our name or in its own name for patents, utility models, design registrations and like rights of exclusion and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment.


DATE: _____

MIKE ROTHE

DATE: _____

NORBERT PRENZEL

DATE: 12.10.2010



ERIC BORGES

DATE: _____

THORE HETTMANN

DATE: _____

ESTHER ZWICK-WALLASCH

U3 Pharma Assignment.doc

ASSIGNMENT

For valuable consideration, we, Mike Rothe, of Elisenstrasse 4, 82152 Krailling, Germany; Norbert Prenzel, of Pentenriederstrasse 32, 82152 Krailling, Germany; Eric Borges, of Roseggergasse 25, 2344 Maria Enzersdorf, Austria; Thore Hettmann, of Hirschgartenallee 14, 80639 Munich, Germany; Esther Zwick-Wallasch, of Fruehlingsstrasse 112, 82131 Gauting, Germany, hereby assign to U3 PHARMA GMBH, a corporation of Germany, having a place of business at:

Fraunhoferstrasse 22
82152 Martinsried
Germany; and

its successors and assigns, (collectively hereinafter called "the Assignee"), the entire right, title and interest throughout the world in the inventions and improvements which are subject of an application for United States Patent signed by us, entitled HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR BINDING PROTEINS, filed on September 26, 2008 as PCT International Application No. PCT/EP2008/08233, which was nationalized in the U.S. on March 25, 2010 and assigned U.S. Application Serial No. 12/680,191, this assignment including said application, any and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our name or in its own name for patents, utility models, design registrations and like rights of exclusion and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment.

DATE: _____

MIKE ROTHE

DATE: _____

NORBERT PRENZEL

DATE: _____

ERIC BORGES

DATE: 13 Oct 2010

Thore Hettmann
THORE HETTMANN

DATE: 13.10.2010

Esther Zwick-Wallasch
ESTHER ZWICK-WALLASCH

U3 Pharma Assignment.doc